Evox Therapeutics Entered into an Agreement with Icahn Mount Sinai to Accelerate Exosome-Delivered AAV Gene Therapy for Heart Disease
Shots
- Evox collaborated with Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) to develop exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology for heart disease
- This novel exoAAV technology is designed to redefine the use of gene therapy in the field of cardiovascular disease by improving the precision of gene delivery to heart muscle cells and cleverly evading the immune response
- The collaboration combines Evox’s leading exosome technology and capabilities with Icahn Mount Sinai’s deep understanding of gene delivery and expertise in cardiovascular research and clinical translation. The collaboration focuses to tackle long-standing challenges in cardiovascular disease
Ref: Globenewswire | Image: Evox Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
